Moderna’s vaccine, suitable for combating Sras-CoV-2 variants, could soon be approved. Europe initiated the process on Friday.
Moderna presented the results of a study on its updated Covid vaccine to combat variants a few days ago. The American laboratory announced that the updated Spikevax vaccine was bivalent, which allowed it to fight against the original strain of the virus and be 8 times more effective against Omicron and other variants.
It would even be ideal as a fall booster dose if the announced variant waves are confirmed.
This Friday, the European Medicines Agency (EMA) announced that it had initiated the ongoing review of this version of Moderna’s vaccine.
“The review will initially focus on data from laboratory studies (non-clinical data) and chemistry, manufacturing and control (CMC) data related to the manufacture of the vaccine,” announces the EMA. “As the company progresses in the development of its bivalent vaccine, the EMA will receive additional data, including data on immune responses against the original strain and the Omicron variant of concern.”
“The review will continue until there is enough data for a formal application. The EMA will share the results of the ongoing review or a possible application in more detail.”